Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Current Deferred Revenue (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Current Deferred Revenue for 5 consecutive years, with $583000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue changed N/A to $583000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $583000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $583000.0 for FY2025, N/A changed from the prior year.
  • Current Deferred Revenue hit $583000.0 in Q4 2025 for Immunocore Holdings, roughly flat from $582000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $33.0 million in Q4 2021 to a low of $582000.0 in Q3 2025.
  • Historically, Current Deferred Revenue has averaged $8.4 million across 3 years, with a median of $594000.0 in 2025.
  • Biggest five-year swings in Current Deferred Revenue: fell 7.96% in 2021 and later tumbled 77.2% in 2022.
  • Year by year, Current Deferred Revenue stood at $33.0 million in 2021, then crashed by 77.2% to $7.5 million in 2022, then plummeted by 92.24% to $583000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for IMCR at $583000.0 in Q4 2025, $582000.0 in Q3 2025, and $594000.0 in Q2 2025.